Endocrinology
News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
News
Findings confirm link between methimazole and risk for acute pancreatitis
CHICAGO – However, there is no evidence of a cumulative dose effect.
Video
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
PHILADELPHIA –
From the Society
Glycemic Control eQUIPS yields success at Dignity Health Sequoia Hospital
The tools available in the GC eQUIPS program are powerful for data analysis and benchmarking.
News
New model for CKD risk draws on clinical, demographic factors
The equation has demonstrated high discrimination and variable calibration across a range of populations.
News
Dapagliflozin approved for reducing HF hospitalization in diabetes
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
News
Certain diabetes drugs may thwart dementia
COPENHAGEN – Intriguing findings from a Danish national registry study.
News
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
News
Machine learning–derived risk score predicts heart failure risk in diabetes patients
Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.
Video
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug